The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of neoadjuvant docetaxel/5-FU/cisplatin in combination with prophylactic pegteograstim in unresectable, locally advanced nasal cavity/paranasal squamous cell carcinoma: KCSG HN18-07.
 
Hojung An
No Relationships to Disclose
 
Bhumsuk Keam
Honoraria - AstraZeneca; Bayer; LG Chem; Lilly; MSD Oncology; Yuhan
Consulting or Advisory Role - Handok; ImmuneOncia; NeoImmuneTech; TiumBio; Trial Informatics
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Seong Hoon Shin
No Relationships to Disclose
 
Min Kyoung Kim
No Relationships to Disclose
 
Sung-Bae Kim
Stock and Other Ownership Interests - Genopeaks
Honoraria - DAEHWA Pharmaceutical; Kalbe Farma; LegoChem Biosciences
Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Ensol Biosciences; ISU Abxis; Lilly (Inst); OBI Pharma
Research Funding - Genzyme (Inst)